Table 4.

Progression-free and Overall survival Analysis of Patients with Squamous or Adeno- and Adenosquamous Carcinoma

	N	Nevent	Adj. HR (PFS)	P†	Nevent	Adj. HR (OS)	P†
Histology
squamous-cell carcinoma	1489	777	referent	—	718	referent	—
adeno- & adenosq. carcinoma	182	97	1.21 (0.98–1.51)	0.083	92	1.25 (1.00–1.56)	0.0499
Age (years)	1671	874	1.00 (0.99–1.01)	0.883	810	1.00 (1.00–1.01)	0.299
Race/Ethnicity
White	1010	530	referent	—	495	referent	—
Black	391	227	1.21 (1.03–1.42)	0.018	215	1.24 (1.05–1.46)	0.010
Hispanic, other	210	92	0.91 (0.73–1.14)	0.419	82	0.87 (0.69–1.11)	0.265
Asian	60	25	0.76 (0.50–1.15)	0.196	18	0.54 (0.33–0.88)	0.013
Performance status
normal, asymptomatic	1192	580	referent	—	526	referent	—
symptomatic, ambulatory	417	251	1.16 (0.99–1.36)	0.061	242	1.22 (1.03–1.43)	0.019
symptomatic, in bed	62	43	1.39 (1.01–1.93)	0.046	42	1.51 (1.09–2.11)	0.014
log Tumor size (cm)	1659	874	1.32 (1.07–1.62)	0.009	810	1.28 (1.04–1.58)	0.021
FIGO stage
IB	348	133	referent	—	113	referent	—
IIB	788	385	1.39 (1.06–1.84)	0.018	357	1.51 (1.12–2.03)	0.006
IIIA	23	17	3.47 (1.96–6.14)	< 0.001	17	4.61 (2.58–8.24)	< 0.001
IIIB	465	302	2.13 (1.59–2.85)	< 0.001	289	2.37 (1.74–3.24)	< 0.001
IVA	47	37	3.46 (2.25–5.31)	< 0.001	34	3.27 (2.08–5.15)	< 0.001
Tumor grade (differentiation)
good	108	51	referent	—	50	referent	—
moderate	1079	552	1.11 (0.83–1.49)	0.481	507	1.04 (0.78–1.40)	0.773
poor	484	271	1.44 (1.06–1.95)	0.018	253	1.35 (0.99–1.84)	0.055

b (a–c) represent the lower 95% confidence limit a, the value b, and the upper 95% confidence limit c.

Progression-free survival (PFS) and overall survival (OS) are given in months; hazard ratios (HR) are unitless.

Tests used:

^†Wald test